Pemex Bonds Surge as Mexico Mandates Debt Deal to Support It
The offering, announced in a filing Tuesday, will consist of a dollar-denominated debt maturing August 2030, in the form of amortizing pre-capitalized securities, or P-Caps, a type instrument used in asset-backed finance.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
AMC Entertainment Holdings, Inc. (AMC): A Bear Case Theory
We came across a bearish thesis on AMC Entertainment Holdings, Inc. on by sabordesoledad. In this article, we will summarize the bulls' thesis on AMC. AMC Entertainment Holdings, Inc.'s share was trading at $3.4400 as of July 21st. AMC Entertainment Holdings (AMC) continues to face structural headwinds in the movie theater business, which was in secular decline even before COVID-19, with the pandemic accelerating negative trends. Per capita attendance has been falling since the early 2000s, and while box office sales have recovered post-pandemic, gains have been driven by ticket price hikes and higher concession sales rather than audience growth. Pixabay/Public Domain Casual moviegoers, a crucial demographic, are increasingly dissuaded by shortened theatrical windows—now averaging around 32 days versus 80–90 pre-pandemic—and the ease of streaming releases. The industry is also contending with a reduced volume of film releases (675 in 2024 vs. 900+ in 2018–2019) and an increasing concentration of box office revenue among a handful of blockbusters. AMC, despite weaker fundamentals and a highly leveraged balance sheet, trades at a premium valuation: 9.9x NTM EV/EBITDA and 11.4x 2025 consensus EBITDA of $449M versus Cinemark's (CNK) 8.2x and 8.6x, respectively. With $4.1B of debt and annual cash interest expense of $400M, AMC remains reliant on equity issuance to de-lever. Revenue in 2024 was still 15% below 2019 levels despite significant price increases—tickets +23% and concessions per attendee +50%—a dynamic that erodes affordability and risks further suppressing attendance. Capex has been cut by 50% to $25k per screen, suggesting underinvestment in maintenance to conserve cash, yet free cash flow remains consistently negative. With only 2M shares left under its current authorization, AMC is expected to seek an expanded share authorization at its 3Q25 AGM, providing a clear catalyst for downside. Previously we covered a on Netflix, Inc. (NFLX) by Margin of Sanity in May 2025, which highlighted the hidden value in Netflix's content library, where amortization accounting obscures the enduring revenue potential of older titles. The company's stock price has appreciated by approximately 5.6% since our coverage as resilient viewership supported the thesis. sabordesoledad shares a contrarian view in AMC, emphasizing structural headwinds from declining attendance, shortened windows, and streaming competition. AMC Entertainment Holdings, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held AMC at the end of the first quarter which was 20 in the previous quarter. While we acknowledge the potential of AMC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Sign in to access your portfolio
Yahoo
11 minutes ago
- Yahoo
Trump says he wants Musk and his companies to thrive in US
(Reuters) -President Donald Trump said on Thursday he would not destroy Elon Musk's companies by taking away federal subsidies and that he wants the billionaire tech-entrepreneur's businesses to thrive. "Everyone is stating that I will destroy Elon's companies by taking away some, if not all, of the large scale subsidies he receives from the U.S. Government. This is not so!," Trump said in a post on Truth Social. "I want Elon, and all businesses within our Country, to THRIVE." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Vericel Corporation (VCEL): A Bull Case Theory
We came across a bullish thesis on Vericel Corporation on Substack by OppCost. In this article, we will summarize the bulls' thesis on VCEL. Vericel Corporation's share was trading at $36.26 as of July 17th. VCEL's trailing and forward P/E were 742.40 and 416.67, respectively according to Yahoo Finance. Vericel Corporation (VCEL) stands at a pivotal inflection point as a newly profitable, high-growth leader in the niche regenerative medicine markets of sports medicine and severe burn care. Having transitioned from a speculative, cash-burning biotech to a disciplined, self-funding commercial enterprise, the company now operates with a debt-free balance sheet, rapidly expanding operating cash flow, and powerful growth catalysts. Its sports medicine franchise, anchored by MACI, remains the cornerstone of performance, generating $197.3 million in 2024 and supported by the transformative launch of MACI Arthro, which expands accessibility through minimally invasive delivery. Early adoption metrics are strong, with a rapidly growing surgeon base and biopsy volumes signaling durable demand. The burn care franchise, comprising Epicel and the recently launched NexoBrid, provides a second growth engine, with burn care revenue up 22% in 2024 and NexoBrid posting 207% year-over-year growth in Q1 2025. With under 7% market penetration across both segments, Vericel's 20%+ revenue growth trajectory is driven by execution rather than market expansion, significantly de-risking the outlook. Profitability is scaling even faster, with 2024 gross margins of 73% and record Q4 margins of 78%, while adjusted EBITDA rose 58% on 20% revenue growth. Capital intensity is set to decline as major investments in its new Burlington manufacturing facility wind down, driving a steep inflection in free cash flow. Valuation remains compelling, with a DCF estimate of $62.50, Owner Earnings valuation of $55.15, and a 5-year forward IRR of 21.5%, supporting a $59 price target, ~48% above the current $39.93. Vericel offers a compelling buy for investors seeking a high-quality, de-risked growth story. Previously, we covered a bullish thesis on Gilead Sciences, Inc. (GILD) by Disruptive analytics in February 2025, which highlighted its resilience despite headwinds from the Inflation Reduction Act, currency strength, and lower COVID-related hospitalizations. The stock has appreciated about 4.53% since our coverage as growth stayed muted, but structural fundamentals remain intact. OppCost shares a similar view on Vericel Corporation (VCEL), emphasizing its high-growth, de-risked regenerative medicine portfolio and accelerating profitability. Vericel Corporation is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 14 hedge fund portfolios held VCEL at the end of the first quarter which was 16 in the previous quarter. While we acknowledge the potential of VCEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
